What does Spyryx Biosciences do?
Spyryx Biosciences is developing next generation therapeutics for obstructive lung diseases. It is based on the discovery of a previously unknown mechanism which the lung used for regulating the fluid on its surfaces. This mechanism is not functional in the lungs of the CF patients which are because of genetic mutations and is thought to be the root cause of the progressive dehydration which leads to the mucus accumulation cycle, immune response, bacterial colonization, tissue scarring and loss of function of the lungs and usually early death.
Spyryx’s product leverages the mechanism discovered and has shown promising results in the preclinical studies by increasing the survival in animal models of CF. the company’s product action is independent of the gene mutations which cause CF, thereby having the capacity to provide disease modifying therapy to the entire population of CF patient.
How much Spyryx Biosciences was funded?
Spyryx Biosciences has raised $18M in Series A funding on May 7th, 2015 from 5AM Ventures, Canaan Partners and Hatteras Venture Partners.
What is next for Spyryx Biosciences?
Spyryx Bioscineces has announced that the MD of general partner of Canaan, Tim Shannon will be joining Spyryx Biosciences as the chairman of Board of Directors. Other joining of the board of directors will be Christy Shaffer, MD of Hatteras Discovery and Brain Daniels, MD of 5 AM. The funding will be used to bring the company its significant expertise in pulmonary drug development which positions it to rapidly advance its CF therapeutics into clinical development and to explore the potential of COPD treatment.
More about Spyryx Biosciences
Spyryx Biosciences was founded on January 1st, 2013 and has its headquarters in North Carolina. It is developing next generation therapeutics for obstructive lung diseases with focus especially on Chronic Obstructive Pulmonary Disease and Cystic Fibrosis.